Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Kumar, S. K., Callender, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Holmberg, L., Htut, M., Huff, C., Kang, Y., Landgren, O., Malek, E., Martin, T., Omel, J., Raje, N., Sborov, D., Singhal, S., Stockerl-Goldstein, K., Tan, C., Weber, D., Johnson-Chilla, A., Keller, J., Kumar, R. 2019; 17 (10): 1155–65


The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.

View details for DOI 10.6004/jnccn.2019.0049

View details for Web of Science ID 000489225300002

View details for PubMedID 31590151